Recurrent bacteremia caused by Rhodococcus equi in a non-neutropenic patient with acute myeloid leukemia in complete remission.
Cid
Ana
A
Haematology, Infectious Diseases and Microbiology Services, Hospital Universitario La Fe, Av. Campanar 21, 46009 Valencia, Spain.
Jarque
Isidro
I
Salavert
Miguel
M
Martín
Guillermo
G
Pérez-Bellés
Carmen
C
Sanz
Miguel A
MA
D000193:Actinomycetales Infections / Q000209:etiology* / Q000382:microbiology; D000328:Adult; D000583:Amikacin / Q000627:therapeutic use; D016470:Bacteremia / Q000209:etiology* / Q000382:microbiology; D002408:Catheters, Indwelling / Q000009:adverse effects; D002442:Ceftazidime / Q000627:therapeutic use; D015377:Cilastatin / Q000627:therapeutic use; D004351:Drug Resistance; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D004917:Erythromycin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use; D016867:Immunocompromised Host; D015479:Leukemia, Myelomonocytic, Acute / Q000150:complications*; D009503:Neutropenia; D018410:Pneumonia, Bacterial / Q000209:etiology; D012008:Recurrence; D016929:Rhodococcus equi; D014640:Vancomycin / Q000627:therapeutic use
D015377:Cilastatin; D004917:Erythromycin; D014640:Vancomycin; D015378:Imipenem; D000583:Amikacin; D002442:Ceftazidime